INmune Bio (NASDAQ:INMB) Shares Up 4.5% – Should You Buy?

INmune Bio, Inc. (NASDAQ:INMB) shares traded up 4.5% on Tuesday . The company traded as high as $1.85 and last traded at $1.74. Approximately 1,792,150 shares were traded during trading, an increase of 56% from the average session volume of 1,145,731 shares. The stock had previously closed at $1.6650.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on INMB shares. Wall Street Zen downgraded INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Lucid Cap Mkts raised INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

INmune Bio Price Performance

The company’s fifty day moving average is $1.44 and its 200-day moving average is $1.44. The stock has a market cap of $47.59 million, a PE ratio of -1.07 and a beta of 0.97.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04.

Institutional Trading of INmune Bio

A number of hedge funds have recently modified their holdings of the stock. Quadrature Capital Ltd purchased a new position in INmune Bio during the fourth quarter valued at approximately $26,000. Intech Investment Management LLC purchased a new stake in INmune Bio in the 2nd quarter worth approximately $26,000. Squarepoint Ops LLC acquired a new stake in shares of INmune Bio during the 3rd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in shares of INmune Bio during the 4th quarter worth approximately $32,000. Finally, Wells Fargo & Company MN increased its holdings in shares of INmune Bio by 79.0% during the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after purchasing an additional 10,970 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.